Clinical Trial Update: Study of Pemetrexed to Treat Recurrent or Progressive Primary Central Nervous System Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating pemetrexed for recurrent or progressive primary central nervous system lymphoma has been withdrawn. The sponsor is the Unive…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Alimta (pemetrexed)

Snippet

Sponsor: University of Florida | Conditions: Primary Central Nervous System Lymphoma | Phase 2 | Status: WITHDRAWN